EndoLynch: High Definition White-Light Colonoscopy vs. Chromoendoscopy for Surveillance of Lynch Syndrome.

Sponsor
Hospital Clinic of Barcelona (Other)
Overall Status
Completed
CT.gov ID
NCT02951390
Collaborator
Fundacion Clinic per a la Recerca Biomédica (Other)
280
1
2
18
15.6

Study Details

Study Description

Brief Summary

Adenomas in Lynch syndrome have an accelerated progression to colorectal cancer (CRC) which might occur despite a regular follow-up. Despite low evidence, high-definition technology (HD) and indigo-carmine chromoendoscopy (CE) are recommended for surveillance in Lynch syndrome.The investigators will conduct a prospective multicenter randomized non-inferiority study. The principal aim is to compare the adenoma detection rate with WLE vs CE. Our hypothesis is that HD-white-light endoscopy (WLE) is not inferior to CE. Therefore - under expert hands - HD-CE does not add any significant advantage over HD-WLE on adenoma detection rate in patients with Lynch syndrome.

Condition or Disease Intervention/Treatment Phase
  • Other: High-definition white-light endoscopy
N/A

Detailed Description

The investigators will conduct a prospective multicenter randomized non-inferiority study. Eligible patients will be those with Lynch syndrome (known germline mutation in mismatch repair genes) who undergo surveillance colonoscopies. Patients will be sequentially assigned in a 1:1 ratio to HD-WLE or HD-CE. The method of stratified randomization based on partial colectomy history will be used to avoid proportion imbalance between groups. Participant centers must have an organized high-risk of CRC clinic and endoscopic unit provided with HD technology. Endoscopists must have a documented high adenoma detection rate and experience in performing CE in patients with high-risk conditions of CRC.

The principal aim is to compare the adenoma detection rate with WLE vs CE. Principal outcome measures will be: 1) adenoma detection rate, defined as the proportion of patients with at least one adenoma in each arm; 2) number of adenomas per patient, defined as the total number of detected adenomas in each arm (HD-WLE or HD-CE) divided by the number of colonoscopies in each arm.

The sample size calculation was determined for a non-inferiority study. Assuming an ADR of 28% with conventional chromoendoscopy in patients with Lynch syndrome, a 15% non-inferiority margin, a one-sided significance level of 0.05 powered at 80% and a 10% of drop-off. Based on these assumptions, it was determined that 122 patients were required for each arm (a total of 244).

Study Design

Study Type:
Interventional
Actual Enrollment :
280 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
High Definition White-Light Colonoscopy Versus Chromoendoscopy for Surveillance of Lynch Syndrome. A Prospective, Multicenter and Randomized Study
Study Start Date :
Jul 1, 2016
Actual Primary Completion Date :
Dec 1, 2017
Actual Study Completion Date :
Dec 31, 2017

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: High-definition white-light endoscopy

High-definition white-light endoscopy without indigo carmine instilation

Other: High-definition white-light endoscopy
The intervention is do not perform chromoendoscopy

No Intervention: High-definition chromoendoscopy

High-definition indigo-carmine chromoendoscopy

Outcome Measures

Primary Outcome Measures

  1. Adenoma detection rate [one year]

    Adenoma detection rate is defined as the proportion of patients with at least one adenoma in each arm

Secondary Outcome Measures

  1. Mean of adenomas per patient [one year]

    the total number of adenomas detected in each group (HD-WLE or HD-CE) divided by the number of colonoscopies in each group

  2. Mean number per patient of total polyps [one year]

  3. Mean number per patient of total serrated lesions [one year]

  4. Polyp detection rate [one year]

  5. Serrated lesions detection rate [one year]

  6. Withdrawal time [30 minutes]

    Extubation time from the cecum to scope removal from the anus, with exception of time taken for any therapeutic intervention

  7. Total procedure time [30 minutes]

    Starting with endoscope insertion and withdrawal time including therapeutic interventions

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with proven pathologic germline mutation in one of the mismatch-repair (MMR) gene (MLH1, MSH2, MSH6, PMS2 or Epcam) who will undergo surveillance colonoscopy
Exclusion Criteria:
  • Patients with total colectomy

  • Concomitant inflammatory bowel disease

  • Inadequate bowel preparation (Boston scale <2 in any colonic segment)

  • Incomplete procedure (without intubation of cecum or ileo-colonic anastomosis)

  • Previous colonoscopy in less than one year

  • Inability to sign informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 María Pellisé. MD. PhD. Barcelona Spain 08036

Sponsors and Collaborators

  • Hospital Clinic of Barcelona
  • Fundacion Clinic per a la Recerca Biomédica

Investigators

  • Principal Investigator: María Pellisé, MD. PhD., Hospital Clinic of Barcelona

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
María Pellisé, MD. PhD. Consultant, Hospital Clinic of Barcelona
ClinicalTrials.gov Identifier:
NCT02951390
Other Study ID Numbers:
  • HCB/2016/0440
First Posted:
Nov 1, 2016
Last Update Posted:
Feb 26, 2018
Last Verified:
Feb 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by María Pellisé, MD. PhD. Consultant, Hospital Clinic of Barcelona
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 26, 2018